65 assets in Rectal Cancer

Therapeutic assets addressing Rectal Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Irinotecan Rectal Cancer	Sun Yat-sen University	P4	BBB (78)
Fluorouracilum Rectal Cancer	Seoul National University Hospital	P3	BBB (77)
Oxaliplatin Rectal Cancer	Sun Yat-sen University	P3	BBB (72)
Capecitabine Rectal Cancer	Tao Zhang	P3	BB (70)
Cetuximab Rectal Cancer	Fudan University	P3	BB (68)
Indocyanine Green Rectal Cancer	National Cancer Center, China	P3	BB (68)
Tipiracil Rectal Cancer	Academic and Community Cancer Research United	P2	BB (67)
Trifluridine Rectal Cancer	Academic and Community Cancer Research United	P2	BB (67)
Sgm-101 Rectal Cancer	Leiden University Medical Center	P2/3	BB (64)
Trastuzumab Rectal Cancer	Academic and Community Cancer Research United	P2	BB (64)
Cyclophosphamide Rectal Cancer	Essen Biotech	P2	B (63)
Ipilimumab Rectal Cancer	Odense University Hospital	P2	B (63)
Nivolumab Rectal Cancer	Odense University Hospital	P2	B (63)
Raltitrexed Rectal Cancer	Fudan University	P2	B (62)
Fludeoxyglucose Rectal Cancer	National Cancer Institute (NCI)	P2	B (61)
Balstilimab Rectal Cancer	City of Hope Medical Center	P2	B (60)
Botensilimab Rectal Cancer	City of Hope Medical Center	P2	B (60)
Pembrolizumab Rectal Cancer	Essen Biotech	P2	B (60)
Regorafenib Rectal Cancer	M.D. Anderson Cancer Center	P2	B (60)
Tas-102 Rectal Cancer	Shandong Cancer Hospital and Institute	P3	B (59)
Encorafenib Rectal Cancer	National Cancer Institute (NCI)	P2	B (58)
1.0% ip-001 for Rectal Cancer	Immunophotonics, Inc.	P2/3	B (57)
ip-001 Rectal Cancer	Immunophotonics, Inc.	P2/3	B (57)
Adalimumab Rectal Cancer	Sun Yat-sen University	P2	CCC (53)
Adebrelimab Rectal Cancer	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	P2	CCC (53)
Cabozantinib Rectal Cancer	University of Colorado, Denver	P2	CCC (53)
Citrus Flavonoid Tablets (Alvenor) Rectal Cancer	Sixth Affiliated Hospital, Sun Yat-sen University	P2	CCC (53)
Fruquintinib Rectal Cancer	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	P2	CCC (53)
Immunoglobulin Half-Ig G1-Kappa/Scfv-H-Ch2-Ch3, Anti-(Homo Sapiens Ctla4 (Cytotoxic T-Lymphocyte-Associated Protein 4, Cd152)) And Anti-(Homo Sapienspdcd1 (Programmed Cell Death 1, Pd-1, Pd1, Cd279)), Monoclonal Antibody, Bispecific Rectal Cancer	M.D. Anderson Cancer Center	P2	CCC (53)
Lorigerlimab Rectal Cancer	M.D. Anderson Cancer Center	P2	CCC (53)
Lparomlimab Rectal Cancer	Sun Yat-sen University	P2	CCC (53)
Muamycin Rectal Cancer	National Cancer Institute (NCI)	P2	CCC (53)
S-1 Rectal Cancer	Tao Zhang	P2	CCC (53)
Serplulimab Rectal Cancer	First Affiliated Hospital of Wenzhou Medical University	P2	CCC (53)
Tisleizumab Rectal Cancer	Tao Zhang	P2	CCC (53)
Tislelizumab Rectal Cancer	brenner baruch	P2	CCC (53)
Toripalimab Rectal Cancer	Sixth Affiliated Hospital, Sun Yat-sen University	P2	CCC (53)
Trastuzumab Deruxtecan Rectal Cancer	Gruppo Oncologico del Nord-Ovest	P2	CCC (53)
Tucatinib Rectal Cancer	Academic and Community Cancer Research United	P2	CCC (53)
Tuvonralimab Rectal Cancer	Sun Yat-sen University	P2	CCC (53)
Zanidatamab Rectal Cancer	Emory University	P2	CCC (53)
Fludarabine Rectal Cancer	Essen Biotech	P1/2	CCC (50)
Abemaciclib Rectal Cancer	M.D. Anderson Cancer Center	P1/2	CC (47)
SX682 Rectal Cancer	M.D. Anderson Cancer Center	P1/2	CC (47)
Temuterkib Rectal Cancer	M.D. Anderson Cancer Center	P1/2	CC (47)
TIL Rectal Cancer	Essen Biotech	P1/2	CC (45)
Dostarlimab Rectal Cancer	University of Iowa	P1	CC (43)
Niraparib Rectal Cancer	University of Iowa	P1	CC (43)
Papaverine Rectal Cancer	City of Hope Medical Center	P1	CC (43)
Nadravaleucel Rectal Cancer	David Wald	P1	CC (41)

Showing 1 to 50 of 65 assets

PreviousPage 1 of 2Next